Elsevier Feb 11 2026 Researchers have identified a promising new speech biomarker that could significantly enrich clinical trials by reducing sample size requirements and enhancing statistical outcomes. By using speech latency, participants who are likely to show a high placebo response can be identified and excluded. The study in Biological Psychiatry , published by Elsevier, showed that when these participants were removed from the main analysis, the treatment-placebo effect increased